By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer “[In the past] walking through ASCO, you were hard pressed to find anybody working in lung cancer, and now you’re hard pressed on finding somebody who is [...]
Researchers, oncologists, pulmonologists, thoracic surgeons, and patients convene at the World Conference on Lung Cancer (WCLC) each year to discuss developments impacting the lung cancer community. This year the International Association for the Study of Lung Cancer (IASLC)’s [...]
GO2 for Lung Cancer is excited to announce the publication of our brand-new handbook, Navigating Small Cell Lung Cancer: 360° of HOPE. Download or order your free hard copy today. When you or someone you love is diagnosed with [...]
On August 19, 2024, the U.S. Food and Drug Administration (FDA) announced their approval of an exciting new treatment combination: Rybrevant (amivantimab-vmjw) combined with Lazcluze (lazertinib). This treatment combination is meant for people who are newly diagnosed with non-small cell [...]
On August 15, 2024, the U.S. Food and Drug Administration (FDA) granted approval for the immunotherapy drug Imfinzi (durvalumab) to be used in combination with chemotherapy (neoadjuvant, treatment given before surgery) as well as on its own after surgery (adjuvant). [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most [...]
Question: I am interested in learning more about clinical trials as a treatment option for my lung cancer. How do I know if I am eligible? How can I find a clinical trial that is a good fit for [...]
GO2 for Lung Cancer Chief Patient Officer Danielle Hicks has been on the front lines confronting lung cancer for very personal reasons. With a family history of lung cancer spanning 3 generations, she is helping unlock the origins of [...]
On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]
Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every [...]